Earlier studies demonstrated that the incretin effect of GIP was severely impaired in patients with uncontrolled T2DM (57); even the pharmacological concentrations of GIP (> 1,000 pM) only marginally stimulate insulin secretion in these patients during hyperglycemic clamp experiments (58). The gene discussed is INS; the disease is type 2 diabetes mellitus.